Are you Dr. Fuller?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 28 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
9600 N Central Expy
Suite 100
Dallas, TX 75231Phone+1 214-692-6941
Summary
- Dr. Timothy Fuller, MD is a board certified ophthalmologist in Dallas, Texas. He is currently licensed to practice medicine in Texas, Pennsylvania, and Utah. He is affiliated with Texas Health Presbyterian Hospital Dallas and Medical City Dallas.
Education & Training
- University of Texas Health Science Center at HoustonResidency, Ophthalmology, 2011 - 2014
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2010 - 2011
- McGovern Medical School at UTHealthClass of 2010
Certifications & Licensure
- TX State Medical License 2014 - 2026
- UT State Medical License 2015 - 2018
- PA State Medical License 2015 - 2016
- American Board of Ophthalmology Ophthalmology
Clinical Trials
Publications & Presentations
PubMed
- 14 citationsRandomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes.Amy C Schefler, Dwain G. Fuller, Rajiv Anand, Timothy Fuller, Chelsey Moore
American Journal of Ophthalmology. 2020-08-01 - 17 citationsOptimal number of angle images for calculating anterior angle volume and iris volume measurements.Lauren S. Blieden, Alice Z. Chuang, Laura A. Baker, Nicholas P. Bell, Timothy Fuller
Investigative Ophthalmology & Visual Science. 2015-05-01
Press Mentions
- NEW PRODUCT APPLICATIONS: Ellex Eye Prime Ultrasound Technology Offers the Ultimate in ImagingAugust 30th, 2019
- Vial Announces Enrollment of the First Patient in the Pivotal Clinical Trial for “OcuCool” Precision Cooling Medical Device, Sponsored by RecensMedical, IncJuly 20th, 2023
- Vial Enrols First Patient in OcuCool System TrialJuly 21st, 2023